NCT00626184View on ClinicalTrials.gov

A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

May 31, 2008

Study Completion Date

July 31, 2008

Conditions
Celiac Disease
Interventions
DRUG

4 dose levels of ALV003

4 dose levels of ALV003 vs placebo

Trial Locations (1)

92103

Clinical Applications Laboratories Inc., San Diego

Sponsors
All Listed Sponsors
lead

Alvine Pharmaceuticals Inc.

INDUSTRY

NCT00626184 - A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease | Biotech Hunter | Biotech Hunter